HC Wainwright reissued their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Monday morning, AnalystRatings.com reports. The firm currently has a $24.00 price target on the stock.
“We use a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 8.0% discount rate and 23% effective tax rate. We assign a 90% probability of approval to DARZALEX in smoldering MM; a 95% probability to ARZERRA in relapsing-remitting multiple sclerosis (RR-MS); an 85% probability to teprotumumab; a 20% probability to enapotamab vedotin in 35% probabilities of approval to tisotumab vedotin for cervical cancer and ovarian cancer, respectively.”,” HC Wainwright’s analyst commented.
A number of other research firms have also commented on GMAB. Bank of America upgraded Genmab A/S from a neutral rating to a buy rating in a research report on Friday, September 13th. JPMorgan Chase & Co. upgraded Genmab A/S from a neutral rating to an overweight rating and set a $23.00 price target on the stock in a research report on Thursday, September 12th. Guggenheim assumed coverage on Genmab A/S in a research report on Monday, August 12th. They set a buy rating on the stock. Royal Bank of Canada assumed coverage on Genmab A/S in a research report on Monday, August 12th. They set an outperform rating and a $23.00 price target on the stock. Finally, Morgan Stanley assumed coverage on Genmab A/S in a research report on Monday, August 12th. They set an overweight rating on the stock. Six analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $23.33.
Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, August 14th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.13. The company had revenue of $116.49 million during the quarter. On average, sell-side analysts predict that Genmab A/S will post 0.42 earnings per share for the current year.
An institutional investor recently bought a new position in Genmab A/S stock. Parametric Portfolio Associates LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 375,476 shares of the company’s stock, valued at approximately $6,937,000. Parametric Portfolio Associates LLC owned about 0.29% of Genmab A/S at the end of the most recent reporting period. 0.83% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
See Also: Support Level
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.